Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).

Tadakazu HisamatsuShingo KatoReiko KunisakiMinoru MatsuuraMasakazu NagahoriSatoshi MotoyaMotohiro EsakiNorimasa FukataSatoko InoueTakeshi SugayaHirotake SakurabaFumihito HiraiKenji WatanabeTakanori KanaiMakoto NaganumaHiroshi NakaseYasuo SuzukiMamoru WatanabeToshifumi HibiMasanori NojimaTakayuki Matsumotonull null

Published in: Journal of gastroenterology (2019)

Continuation of thiopurines > 6 months offers no clear benefit over scheduled ADA monotherapy. CFCR, ER, and ADA trough level at week 52 were not significantly different between groups. ER at week 0 may be involved in better long-term clinical outcomes.

Keyphrases

clinical trial
open label
placebo controlled
double blind
endoplasmic reticulum
estrogen receptor
phase ii
study protocol
breast cancer cells
phase iii
rheumatoid arthritis
combination therapy
juvenile idiopathic arthritis
randomized controlled trial
newly diagnosed
ulcerative colitis
hidradenitis suppurativa